Tech Center 1600 • Art Units: 1623 1626
This examiner grants 79% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17570737 | Compositions and Methods for Inhibiting and Treating Coronavirus Infections | Non-Final OA | The Regents of the University of California |
| 18558148 | CRYSTAL FORM VII OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME | Non-Final OA | LG CHEM, LTD. |
| 18558142 | SULFATE CRYSTALS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PRODUCING SAME | Non-Final OA | LG CHEM, LTD. |
| 18557866 | CRYSTALLINE FORM V OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND METHOD FOR PREPARING SAME | Non-Final OA | LG CHEM, LTD. |
| 17059464 | Compounds and Methods for Treating Bacterial Infections | Non-Final OA | NEW YORK UNIVERSITY |
| 17594754 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | Non-Final OA | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
| 18688300 | GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PH | Non-Final OA | Neurop, Inc. |
| 18571909 | FUSED TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Non-Final OA | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| 18564881 | PROCESS FOR THE PREPARATION OF BIS-RESORCINYL-TRIAZINES | Non-Final OA | SUQIAN COSMOS CHEMICAL CO., LTD |
| 18561189 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | Non-Final OA | ReWind Therapeutics NV |
| 18220867 | NANOMATERIALS COMPRISING AN IONIZABLE LIPID | Non-Final OA | Beam Therapeutics Inc. |
| 18280177 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | Non-Final OA | Hongjian ZHANG |
| 18276309 | Compounds and Their Use as PDE4 Activators | Non-Final OA | Mironid Limited |
| 17639540 | PHENAZINE DERIVATIVE AND USE THEREOF FOR THE TREATMENT OF CANCER | Final Rejection | UNIVERSITE D'AIX-MARSEILLE |
| 18272435 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | Non-Final OA | United States of America, as represented by the Secretary, Department of Health and Human Services |
| 17376829 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Non-Final OA | NOVARTIS PHARMA AG |
| 18256107 | HETEROGENEOUS REDOX CATALYTIC SYSTEM | Non-Final OA | UNIVERSIDAD DEL PAÍS VASCO - EUSKAL HERRIKO UNIBERTSITATEA |
| 17184431 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | Non-Final OA | TES Pharma S.r.l. |
| 18252098 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | Non-Final OA | BIOFRONT LTD |
| 17637690 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | Non-Final OA | BEIJING TIDE PHARMACEUTICAL CO., LTD. |
| 18095596 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | Non-Final OA | BiSiChem Co., Ltd. |
| 17623109 | HEPATIC FIBROSIS-INHIBITING AGENT AND BROWN FAT CELL-ACTIVATING AGENT CONTAINING TAXIFOLIN | Non-Final OA | Seaknit Biological Technology Co., Ltd. |
| 17059481 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Non-Final OA | Nanjing Immunophage Biomedical Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy